Antitumor effects of IOX1 combined with bevacizumab-induced apoptosis and immunity on colorectal cancer cells
- 14 August 2024
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 141, 112896
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal CancerJAMA, 2023
- IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylationBiochemical Pharmacology, 2023
- Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemiaCancer, 2022
- Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal CancerTargeted Oncology, 2022
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell ProliferationReproductive Sciences, 2020
- Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancerBiomedicine & Pharmacotherapy, 2019
- Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal CancerJAMA Oncology, 2019
- Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerCochrane Database of Systematic Reviews, 2016
- A Cell‐Permeable Ester Derivative of the JmjC Histone Demethylase Inhibitor IOX1ChemMedChem, 2014